Sun Pharma research co gets Sebi nod to raise Rs 250 crore

Drug discovery firm Sun Pharma Advanced Research Company (SPARC) has received markets regulator Sebi's approval to raise up to Rs 250 crore through a rights issue.

The company, which filed draft papers on September 18, 2015, seeking clearance from Sebi to raise funds through the rights issue, obtained the approval on January 22.

As per draft papers filed with the Securities and Exchange Board of India (Sebi), the company will issue equity shares "aggregating up to Rs 25,000 lakh to our existing equity shareholders on a rights basis."

In a rights issue, shares are issued to existing investors as per their holding at pre-determined price and ratio.

ALSO READ: Sun Pharma, SPARC shares down over 2% on rejected anti-epileptic drug application

The proceeds of the issue will be utilised for meeting costs related to pharmaceutical research and development, clinical trials and for other general corporate purposes. 

SPARC was de-merged from Sun Pharma as a pharma research and drug discovery company in 2007.

EY, Inga Capital are the lead managers to the issue.

In May, the company's board had approved the proposal to raise up to Rs 250 crore through a rights issue.    

On Monday, the shares of the Sun Pharma Advanced Research Company closed up 1.86% or Rs 5.10 at Rs 279.70 per scrip on the BSE.